Oxford/AstraZeneca’s nasal spray vaccine performed poorly in an early-stage study, squashing hopes for a quick advancement of the duo’s original formulation...
The pharmaceutical giant, still riding high on the sales of Comirnaty and Paxlovid, is looking to a future of innovative oncology drugs and vaccines based...
AbbVie may have doubled in size since the Allergan acquisition, but nearly half the company’s revenue, and a large chunk of its potential future growth,...
2022 has been marked by the first year of leadership under CEO Joaquin Duato and the anticipated separation of the company’s consumer health busines...
Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating...
It might seem like luck for a company to trip over a multi-billion dollar COVID treatment already lurking in its pipeline – but perhaps not so...
Slowly but steadily, Bayer is starting to emerge from under the cloud cast by litigation over the weed killer.
Following its Play to Win strategy, Sanofi looks to the future with a new corporate identity and charitable foundations.
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by...
Shellenberger: Biden Is Failing The World Authored by Michael Shellenberg via Substack, The world desperately needs energy and yet President...
How The EU Is Forcing Twitter To Censor (And Musk Can't Stop It) Authored by Robert Kogon via The Brownstone Institute, Twitter is obviously...
Understanding The Caucasus Region The Caucasus Region has been engulfed in a territorial dispute between Armenia and Azerbaijan over the...
Bowmo™, Inc. (OTCMKTS: BOMO) accumulation continues as new investors jump on board looking for the next big OTC runner. The Company recently completed...
When it comes to household finances, there’s one debt-stresser that rules them all
The $31 Trillion Dollar Question – Can The Fed Afford To Pivot? Authored by Tom Luongo via Gold, Goats, 'n Guns blog, In my other role...
You've heard of Sicily and Tuscany but probably not Friuli Venezia Giulia.
The autocratic regime of Ayatollah Khamenei is coming under pressure like never before.
Overview: The markets seem to lack conviction today. Stocks in the Asian Pacific region advanced. Europe’s Stoxx 600 is giving up its earlier advance,...
Futures Slide As OPEC+ Cut Sparks Gas Inflation Fears And "Tighter For Longer" Fed Two days ago, when stocks were melting up even as oil was...
The number one fact in play right now for investors is risk aversion. According to Bank of America strategists, professional money managers are currently...
Hardware hobbyists wanting to get their hands on some juicy single-board Raspberry Pi kit to power low cost electronics projects have been having a frustrating...
- by New Deal democratBack in August I highlighted some epidemiological work by Trevor Bedford about what endemic COVID is likely to look like, based...
Overview: Hopes that the global tightening cycle is entering its last phase supplied the fodder for a continued dramatic rally in equities and bonds....
Three infrastructure investments to buy as war and inflation rage offer ways to overcome ongoing economic risks in pursuit of precious profits. The three...
Liz Truss took over as prime minister with an ambitious plan to cut taxes by the most since 1972 – investors balked after it wasn’t clear...
Thousands of ancient genomes have been sequenced to date. A Nobel Prize highlights tremendous opportunities for aDNA, as well as challenges related to...
Roubini: The Stagflationary Debt Crisis Is Here Authored by Nouriel Roubini via Project Syndicate, The Great Moderation has given way to...
Credit Suisse CEO Ulrich Koerner began his tenure in 2022 and is set to reveal the company's turnaround plan later in October.
If governments fail to take action, the cost of living crisis will worsen the impact of the pandemic this winter, and vice versa.